GLP1R and type 2 diabetes mellitus: Data from cardiovascular outcome trials (CVOTs) conducted with various members of the class in people with T2D show that the reduction in the risk of major adverse cardiac events observed with GLP-1 RA therapy is primarily driven by a consistent decrease in stroke rates [20].